Lantern Pharma Financials
| LTRN Stock | USD 5.99 0.01 0.17% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0054 | 0.0057 |
|
| |||||
| Current Ratio | 14.43 | 16.1831 |
|
|
The financial analysis of Lantern Pharma is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Lantern Pharma includes many different criteria found on its balance sheet. For example, investors should never minimize Lantern Pharma's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Lantern Pharma's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Lantern Pharma.
Net Income |
|
With this module, you can analyze Lantern financials for your investing period. You should be able to track the changes in Lantern Pharma individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Lantern | Select Account or Indicator |
Understanding current and past Lantern Pharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Lantern Pharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Lantern Pharma's assets may result in an increase in income on the income statement.
The data published in Lantern Pharma's official financial statements usually reflect Lantern Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Lantern Pharma. For example, before you start analyzing numbers published by Lantern accountants, it's critical to develop an understanding of what Lantern Pharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Lantern Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lantern Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Lantern Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Lantern Pharma. Please utilize our Beneish M Score to check the likelihood of Lantern Pharma's management manipulating its earnings.
Lantern Pharma Stock Summary
Lantern Pharma competes with Home Federal, Betterware, Provident Bancorp, Heartland Financial, and Nordea Bank. Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. The company was incorporated in 2013 and is headquartered in Dallas, Texas. Lantern Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US51654W1018 |
| CUSIP | 51654W101 |
| Location | Texas; U.S.A |
| Business Address | 1920 McKinney Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.lanternpharma.com |
| Phone | 972 277 1136 |
| Currency | USD - US Dollar |
You should never invest in Lantern Pharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Lantern Stock, because this is throwing your money away. Analyzing the key information contained in Lantern Pharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Lantern Pharma Key Financial Ratios
Generally speaking, Lantern Pharma's financial ratios allow both analysts and investors to convert raw data from Lantern Pharma's financial statements into concise, actionable information that can be used to evaluate the performance of Lantern Pharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Lantern Pharma reports annually and quarterly.| Return On Equity | -0.33 | ||||
| EBITDA | (17.7 M) | ||||
| Net Income | (15.96 M) |
Lantern Pharma Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 1.4M | 20.4M | 74.0M | 58.8M | 43.6M | 36.4M | |
| Other Current Liab | 489.3K | 552.3K | 2.2M | 2.7M | 2.5B | 2.6B | |
| Net Tangible Assets | 943.0K | 19.7M | 71.6M | 56.0M | 64.4M | 32.6M | |
| Net Debt | (1.2M) | (19.1M) | (51.3M) | (37.1M) | (21.7M) | (22.8M) | |
| Retained Earnings | (6.8M) | (12.7M) | (25.0M) | (39.3M) | (55.2M) | (52.5M) | |
| Accounts Payable | 489.3K | 552.3K | 2.2M | 2.7M | 2.5M | 1.6M | |
| Cash | 1.2M | 19.2M | 51.5M | 37.2M | 21.9M | 24.1M | |
| Total Liab | 489.3K | 660.8K | 2.4M | 2.8M | 2.7M | 1.8M | |
| Net Invested Capital | 929.3K | 19.8M | 71.6M | 56.0M | 40.9M | 34.7M | |
| Total Current Assets | 1.2M | 20.2M | 72.7M | 58.7M | 43.3M | 36.1M | |
| Capital Stock | 25.4K | 622.0 | 1.1K | 1.1K | 1.1K | 1.0K | |
| Net Working Capital | 743.5K | 19.7M | 70.4M | 55.9M | 40.7M | 34.3M |
Lantern Pharma Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Lantern Pharma. It measures of how well Lantern is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Lantern Pharma brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Lantern had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Lantern Pharma has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (5.7K) | (16.1K) | (19.5M) | 207.1K | (583.5K) | (612.7K) | |
| Change In Cash | 786.9K | 18.0M | 33.3M | (14.8M) | (15.8M) | (15.0M) | |
| Free Cash Flow | (2.1M) | (5.7M) | (10.6M) | (12.8M) | (14.4M) | (13.6M) | |
| Depreciation | 1.6K | 3.4K | 6.8K | 10.1K | 174.8K | 183.6K | |
| Net Income | (2.4M) | (5.9M) | (12.4M) | (14.3M) | (16.0M) | (15.2M) | |
| End Period Cash Flow | 1.2M | 19.2M | 52.5M | 37.7M | 21.9M | 24.4M | |
| Change To Netincome | 117.8K | 1.2M | 1.2M | 1.7M | 2.0M | 2.1M |
Lantern Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Lantern Pharma's current stock value. Our valuation model uses many indicators to compare Lantern Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Lantern Pharma competition to find correlations between indicators driving Lantern Pharma's intrinsic value. More Info.Lantern Pharma is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . At this time, Lantern Pharma's Return On Equity is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Lantern Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Lantern Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lantern Pharma's earnings, one of the primary drivers of an investment's value.Lantern Pharma Systematic Risk
Lantern Pharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Lantern Pharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Lantern Pharma correlated with the market. If Beta is less than 0 Lantern Pharma generally moves in the opposite direction as compared to the market. If Lantern Pharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Lantern Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Lantern Pharma is generally in the same direction as the market. If Beta > 1 Lantern Pharma moves generally in the same direction as, but more than the movement of the benchmark.
About Lantern Pharma Financials
What exactly are Lantern Pharma Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Lantern Pharma's income statement, its balance sheet, and the statement of cash flows. Potential Lantern Pharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Lantern Pharma investors may use each financial statement separately, they are all related. The changes in Lantern Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lantern Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Lantern Pharma Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Lantern Pharma is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Lantern has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Lantern Pharma's financials are consistent with your investment objective using the following steps:- Review Lantern Pharma's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Lantern Pharma's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Lantern Pharma's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Lantern Pharma's stock is overvalued or undervalued.
Today, most investors in Lantern Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lantern Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Lantern Pharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Lantern Pharma April 18, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Lantern Pharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Lantern Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Lantern Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Lantern Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Lantern Pharma's daily price indicators and compare them against related drivers.
| Downside Deviation | 8.8 | |||
| Information Ratio | 0.1028 | |||
| Maximum Drawdown | 49.16 | |||
| Value At Risk | (13.82) | |||
| Potential Upside | 18.37 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Lantern Stock analysis
When running Lantern Pharma's price analysis, check to measure Lantern Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantern Pharma is operating at the current time. Most of Lantern Pharma's value examination focuses on studying past and present price action to predict the probability of Lantern Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantern Pharma's price. Additionally, you may evaluate how the addition of Lantern Pharma to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Lantern Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Return On Assets (0.22) | Return On Equity (0.33) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.